The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EMMA | -55.58% | -98.48% | -56.68% | -100% |
| S&P | +13.19% | +87.83% | +13.42% | +125% |
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company was founded on March 20, 1987 and is headquartered in Torrance, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.82M | -47.6% |
| Gross Profit | $2.67M | -48.1% |
| Gross Margin | 94.68% | -0.8% |
| Market Cap | $0.83M | -84.7% |
| Market Cap / Employee | $0.02M | 0.0% |
| Employees | 35 | -36.4% |
| Net Income | -$1.14M | 48.0% |
| EBITDA | -$0.37M | -162.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.89M | -41.9% |
| Accounts Receivable | $2.07M | -55.0% |
| Inventory | 1.3 | -19.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.84M | 8.0% |
| Short Term Debt | $28.55M | 2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.74% | 0.0% |
| Return On Invested Capital | 51.40% | -151.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.91M | 0.4% |
| Operating Free Cash Flow | -$2.91M | 0.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.03 | -0.01 | -0.02 | -0.01 | -87.82% |
| Price to Sales | 0.24 | 0.03 | 0.07 | 0.06 | -81.51% |
| Price to Tangible Book Value | -0.03 | -0.01 | -0.02 | -0.01 | -87.82% |
| Enterprise Value to EBITDA | 43.74 | -58.48 | -33.58 | -88.35 | -243.02% |
| Total Debt | $32.54M | $33.13M | $32.98M | $32.39M | 3.02% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
